

浏览全部资源
扫码关注微信
1.上海中医药大学 附属曙光医院 宝山分院,上海 201999
2.上海中医药大学 附属宝山医院,上海 201999
3.上海中医药大学 附属曙光医院,上海 201203
4.上海中医药大学 中医肾病研究所, 肝肾疾病病证教育部重点实验室,上海市中医临床重点实验室,上海 201203
Received:26 April 2023,
Published Online:01 September 2023,
Published:20 March 2024
移动端阅览
杨超茅,张顺宵,李园园等.六味地黄汤加减联合氯沙坦钾对糖尿病肾病大鼠ACE1/AngⅡ/AT1R轴及肠道菌群的影响[J].中国实验方剂学杂志,2024,30(06):1-9.
YANG Chaomao,ZHANG Shunxiao,LI Yuanyuan,et al.Modified Liuwei Dihuangtang Combined with Losartan Potassium Regulates ACE1/AngⅡ/AT1R Axis and Intestinal Flora in Rat Model of Diabetic Kidney Disease[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(06):1-9.
杨超茅,张顺宵,李园园等.六味地黄汤加减联合氯沙坦钾对糖尿病肾病大鼠ACE1/AngⅡ/AT1R轴及肠道菌群的影响[J].中国实验方剂学杂志,2024,30(06):1-9. DOI: 10.13422/j.cnki.syfjx.20232122.
YANG Chaomao,ZHANG Shunxiao,LI Yuanyuan,et al.Modified Liuwei Dihuangtang Combined with Losartan Potassium Regulates ACE1/AngⅡ/AT1R Axis and Intestinal Flora in Rat Model of Diabetic Kidney Disease[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(06):1-9. DOI: 10.13422/j.cnki.syfjx.20232122.
目的
2
基于血管紧张素转换酶1(ACE1)/血管紧张素Ⅱ(AngⅡ)/血管紧张素Ⅱ1型受体(AT1R)轴,探讨六味地黄汤加减防治糖尿病肾病(DKD)肾脏损伤的可能作用机制。
方法
2
随机将50只雄性SD大鼠分为正常组8只,造模组42只,造模组大鼠高糖高脂饲料喂养6周后,予一次性腹腔注射链脲佐菌素(STZ)35 mg
·
kg
-1
诱导建立DKD大鼠模型。造模成功后随机分为模型组、中药组(六味地黄汤加减颗粒剂21 g
·
kg
-1
)、西药组(氯沙坦钾33 mg
·
kg
-1
)、中西药组(氯沙坦钾33 mg
·
kg
-1
联合六味地黄汤加减颗粒剂21 g
·
kg
-1
),连续灌胃8周后检测各组大鼠空腹血糖(FBG)、尿蛋白(Up)、尿素氮(Bun)、血肌酐(SCr);酶联免疫吸附测定法(ELISA)检测血清ACE1、AngⅡ、AT1R水平;蛋白免疫印迹法(Western blot)检测各组大鼠肾组织ACE1、AngⅡ、AT1R蛋白表达水平;苏木素-伊红(HE)、马松(Masson)、过碘酸雪夫氏(PAS)染色后观察肾组织病理形态学改变;采集各组大鼠粪便标本进行16S rDNA高通量测序分析。
结果
2
与正常组比较,模型组Up、FBG、Bun、SCr、ACE1、AngⅡ、AT1R水平显著升高(
P
<
0.01),肾组织病变严重,ACE1、AngⅡ、AT1R蛋白表达显著增加(
P
<
0.01),厚壁菌门/拟杆菌门(F/B)升高,乳杆菌属的物种丰度下降,穆氏菌属、双歧杆菌属的物种丰度升高;与模型组比较,各给药组Bun、SCr、ACE1、AngⅡ、AT1R水平均显著下降(
P
<
0.01),肾脏病变程度有所改善,中药组、中西药组Up、FBG水平均显著下降(
P
<
0.01),西药组和中西药组的ACE1、AngⅡ、AT1R蛋白,中药组的AngⅡ蛋白表达显著减少(
P
<
0.01)、中药组ACE1、AT1R蛋白表达明显减少(
P
<
0.05),中药组、中西药组的F/B降低;西药组和中药组布劳特氏菌属的物种丰度升高,中药组、中西药组乳杆菌属、瘤胃球菌科未定属、双歧杆菌属的物种丰度升高,穆氏菌属的物种丰度下降,中药组、中西药组Chao 1和Ace指数明显增加(
P
<
0.05);与西药组比较,中西药组Up水平均显著下降(
P
<
0.01),中西药组的Bun水平明显降低(
P
<
0.05);中西药组ACE1、AT1R水平显著降低(
P
<
0.01),ACE1、AngⅡ、AT1R蛋白表达明显减少(
P
<
0.05),肾脏病变程度改善较明显,双歧杆菌属的物种丰度升高,Chao 1和Ace指数明显增加(
P
<
0.05)。
结论
2
六味地黄汤加减联合氯沙坦钾可通过调节ACE1/AngⅡ/AT1R轴减轻肾脏纤维化,提升大鼠乳杆菌属、双歧杆菌属的物种丰度,降低穆氏菌属的物种丰度,并改善肠道菌群的丰富度、均匀度,减轻肾脏病理损伤。
Objective
2
To explore the mechanism of modified Liuwei Dihuangtang in preventing and treating renal injury in diabetic kidney disease (DKD) via the angiotensin-converting enzyme 1 (ACE1)/angiotensin Ⅱ (AngⅡ)/angiotensin Ⅱ type 1 receptor (AT1R) axis.
Method
2
Fifty male SD rats were randomized into a normal group (
n
=8) and a modeling group (
n
=42). The rats in the modeling group were fed with a high-sugar and high-fat diet for 6 weeks and intraperitoneally injected with 35 mg
·
kg
-1
streptozotocin (STZ) to establish the model of DKD. After successful modeling, the rats were randomized into model, traditional Chinese medicine (modified Liuwei Dihuangtang granules 21 g
·
kg
-1
), western medicine (losartan potassium, 33 mg
·
kg
-1
), and integrated Chinese and western medicine (losartan potassium 33 mg
·
kg
-1
combined with modified Liuwei Dihuangtang granules 21 g
·
kg
-1
) groups. The levels of fasting blood glucose (FBG), urinary protein (Up), blood urea nitrogen (Bun), and serum creatinine (SCr) were measured in each group after 8 consecutive weeks of drug intervention. Enzyme-linked immunosorbent assay was employed to determine the serum levels of ACE1, AngⅡ, and AT1R. Western blot was employed to measure the protein levels of ACE1, AngⅡ, and AT1R in the renal tissue. The pathological and morphological changes of the renal tissue were observed after hematoxylin-eosin (HE) staining, Masson staining, and periodic acid Schiff 's (PAS) staining. The fecal samples of rats in each group were collected for 16S rDNA high-throughput sequencing
.
Result
2
Compared with the normal group, the model group showed elevated levels of Up, FBG, Bun, SCr, ACE1, AngⅡ, and AT1R (
P
<
0.01), serious lesions in the renal tissue, up-regulated protein levels of ACE1, AngⅡ, and AT1R (
P
<
0.01), increased Firmicutes/Bacteroidetes (F/B) ratio, decreased relative abundance of
Lactobacillus
, and increased relative abundance of
Moralella
and
Bifidobacteria
. Compared with the model group, drug intervention lowered the levels of Bun, SCr, ACE1, AngⅡ, and AT1R (
P
<
0.01) and alleviated the pathological changes in the renal tissue. Chinese medicine and integrated Chinese and western medicine lowered the levels of Up and FBG (
P
<
0.01), and western medicine and integrated Chinese and western medicine down-regulated the protein levels of ACE1, AngⅡ, and AT1R. In addition, Chinese medicine down-regulated the protein levels of AngⅡ (
P
<
0.01) as well as ACE1 and AT1R (
P
<
0.05). Chinese medicine and integrated Chinese and western medicine decreased the F/B ratio, and western medicine and Chinese medicine increased the relative abundance of
Blautia
. Chinese medicine and integrated Chinese and western medicine increased the relative abundance of
Lactobacillus
,
Ruminococcus
undetermined genera, and
Bifidobacteria
, decreased the relative abundance of
Moralella
, and increased the Chao 1 and Ace indexes (
P
<
0.05). Compared with the western medicine group, the integrated Chinese and western medicine group showed lowered levels of Up (
P
<
0.01), Bun (
P
<
0.05), and ACE1 and AT1R (
P
<
0.01), down-regulated protein levels of ACE1, AngⅡ, and AT1R (
P
<
0.05), alleviated pathological changes in the renal tissue, increased relative abundance of
Bifidobacteria
, and increased Chao 1 and Ace indexes (
P
<
0.05).
Conclusion
2
Modified Liuwei Dihuangtang combined with losartan potassium can mitigate renal fibrosis by regulating the ACE1/AngⅡ/AT1R axis, increasing the relative abundance of
Lactobacillus
and
Bifidobacterium
, reducing the relative abundance of
Moralella
, improving the richness and evenness of intestinal flora, and alleviating pathological damage in the renal tissue.
RUIZ-ORTEGA M , RODRIGUES-DIEZ R R , LAVOZ C , et al . Special issue "diabetic nephropathy: Diagnosis, prevention and treatment" [J]. J Clin Med , 2020 , 9 ( 3 ): 813 .
HOU J H , ZHU H X , ZHOU M L , et al . Changes in the spectrum of kidney diseases: An analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China [J]. Kidney Dis (Basel) , 2018 , 4 ( 1 ): 10 - 19 .
李嘉欣 , 马婷婷 , 南一 , 等 . 糖尿病肾病发病机制研究进展 [J]. 临床肾脏病杂志 , 2019 , 19 ( 11 ): 860 - 864 .
WYSOCKI J , YE M , KHATTAB A M , et al . Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy [J]. Kidney Int , 2017 , 91 ( 6 ): 1336 - 1346 .
黄雅兰 , 黄国东 , 蔡林坤 , 等 . 壮药复方仙草颗粒治疗早期糖尿病肾病的临床疗效及对患者内皮功能、血液流变学、免疫功能的影响 [J]. 中国全科医学 , 2020 , 23 ( 24 ): 3086 - 3093 .
朱文婧 , 卓宇苗 , 梁钊雄 . 阿魏酸哌嗪辅助治疗糖尿病肾病的效果及对患者肾功能、血液流变学指标的影响 [J]. 海南医学 , 2020 , 31 ( 7 ): 835 - 837 .
吉晶 , 何立群 . 抗纤灵方对5/6肾切除大鼠肾纤维化及ACE-AngⅡ-AT1R轴的影响 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 1 ): 57 - 62 .
ALICIC R Z , ROONEY M T , TUTTLE K R . Diabetic kidney disease: Challenges, progress, and possibilities [J]. Clin J Am Soc Nephrol , 2017 , 12 ( 12 ): 2032 - 2045 .
ZHANG L , LONG J , JIANG W , et al . Trends in chronic kidney disease in China [J]. N Engl J Med , 2016 , 375 ( 9 ): 905 - 906 .
LEHTO M , GROOP P H . The gut-kidney axis: Putative interconnections between gastrointestinal and renal disorders [J]. Front Endocrinol (Lausanne) , 2018 , doi: 10.3389/fendo.2018.00553 http://dx.doi.org/10.3389/fendo.2018.00553 .
杨超茅 , 李园园 , 张顺宵 , 等 . 肠道菌群与局部肾素-血管紧张素系统对糖尿病肾病的影响及中医药研究进展 [J]. 中国实验方剂学杂志 , 2023 , 15 ( 29 ): 242 - 248 .
杨超茅 , 杨志新 , 曹翼 , 等 . 糖肾地黄汤联合氯沙坦钾片治疗早中期糖尿病肾病的临床疗效及对患者肾素-血管紧张素系统的影响 [J]. 辽宁中医杂志 , 2020 , 47 ( 12 ): 86 - 89 .
李启航 , 陈文斌 , 孙珑昱 , 等 . 常用糖尿病肾病动物模型研究概述 [J]. 中华内分泌代谢杂志 , 2020 , 36 ( 3 ): 257 - 262 .
刘卿 , 周于禄 , 裴奇 , 等 . 六味地黄丸对糖尿病肾病大鼠肾脏保护作用的研究 [J]. 湖南中医药大学学报 , 2007 , 27 ( 6 ): 40 - 43 .
张宏 , 王旭昀 , 刘美奇 , 等 . 中药含药血清实验动物灌胃给药剂量探讨 [J]. 吉林中医药 , 2015 ( 6 ): 623 - 625 .
MEIJERS B K , EVENEPOEL P . The gut-kidney axis:Indoxyl sulfate, p-cresyl sulfate and CKD progression [J]. Nephrol Dial Transplant , 2011 , 26 ( 3 ): 759 - 761 .
RITZ E . Intestinal-renal syndrome: Mirage or reality? [J]. Blood Purif , 2011 , 31 ( 1/3 ): 70 - 76 .
CROMMEN S , SIMON M C . Microbial regulation of glucose metabolism and insulin resistance [J]. Genes , 2017 , 9 ( 1 ): 10 .
PICKARD J M , ZENG M Y , CARUSO R , et al . Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease [J]. Immunol Rev , 2017 , 279 ( 1 ): 70 - 89 .
LI L , MA L , FU P . Gut microbiota-derived short-chain fatty acids and kidney diseases [J]. Drug Des Devel Ther , 2017 , 11 : 3531 - 3542 .
LEYLABADLO H E , SANAIE S , HERAVI F S , et al . From role of gut microbiota to microbial-based therapies in type 2-diabetes [J]. Infection Genetics and Evolution , 2020 , doi: 10.1016/j.meegid.2020.104268 http://dx.doi.org/10.1016/j.meegid.2020.104268 .
孙卫卫 , 滕福斌 , 刘忠杰 , 等 . 王耀献从辨机理论论治糖尿病肾病 [J]. 中华中医药杂志 , 2017 , 32 ( 8 ): 3394 - 3396 .
陈彦旭 , 金彩云 , 金智生 , 等 . 基于Wnt/ β -catenin信号通路探讨红芪多糖对糖尿病肾病db/db小鼠作用机制 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 21 ): 74 - 80 .
冯辉 , 刘永林 , 陈益民 . 痰、瘀、毒与糖尿病肾病 [J]. 江西中医药大学学报 , 2016 , 28 ( 2 ): 11 - 12 .
杨超茅 , 杨志新 , 马晓玲 . AGEs-RAGE信号通路在糖尿病肾病中的作用机制及中医药研究进展 [J]. 中医学报 , 2019 , 34 ( 9 ): 1864 - 1868 .
王晨 , 程龙 , 石璐 , 等 . TGF- β 相关信号通路在糖尿病病理机制中的作用及中医药干预研究进展 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 21 ): 254 - 263 .
TODA N , MUKOYAMA M , YANAGITA M , et al . CTGF in kidney fibrosis and glomerulonephritis [J]. Inflamm Regen , 2018 , doi: 10.1186/s41232-018-0070-0 http://dx.doi.org/10.1186/s41232-018-0070-0 .
戴新新 , 蔡红蝶 , 宿树兰 , 等 . 地黄叶对糖尿病肾病大鼠肠道菌群的调节作用 [J]. 药学学报 , 2017 , 52 ( 11 ): 1683 - 1691 .
LI X W , CHEN H P , HE Y Y , et al . Effects of rich-polyphenols extract of Dendrobium loddigesii on anti-diabetic, anti-inflammatory, anti-oxidant, and gut microbiota modulation in db/db mice [J]. Molecules , 2018 , 23 ( 12 ): 3245 .
VAZIRI N D , WONG J , PAHL M , et al . Chronic kidney disease alters intestinal microbial flora [J]. Kidney Int , 2013 , 83 ( 2 ): 308 - 315 .
KARLSSON F H , TREMAROLI V , NOOKAEW I , et al . Gut metagenome in European women with normal, impaired and diabetic glucose control [J]. Nature , 2013 , 498 ( 7452 ): 99 - 103 .
刘枘岢 , 陈毅光 , 李雯翀 , 等 . 2型糖尿病患者肠道菌群的变化及其与代谢指标的关系 [J]. 实用医学杂志 , 2019 , 35 ( 20 ) : 3208 - 3213 .
RINNINELLA E , RAOUL P , CINTONI M , et al . What is the healthy gut microbiota composition? A changing ecosystem across age, environment diet, and diseases [J]. Microorganisms , 2019 , 7 ( 1 ): 14 .
WANG G , SI Q , YANG S , et al . Lactic acid bacteria reduce diabetes symptoms in mice by alleviating gut microbiota dysbiosis and inflammation in different manners [J]. Food Funct , 2020 , 11 ( 7 ): 5898 - 5914 .
DOBRANOWSKI P A , TANG C , SAUVÉ J P , et al . Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice [J]. Gut Microbes , 2019 , 10 ( 5 ): 578 - 598 .
宋丹丹 , 米焱 , 王彩丽 . 基于高通量测序对糖尿病肾脏疾病和2型糖尿病肠道菌群失调模式的研究 [J]. 临床肾脏病杂志 , 2021 , 21 ( 11 ): 887 - 894 .
SHEN F , ZHENG R D , SUN X Q , et al . Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease [J]. Hepatobiliary Pancreatic Dis Int , 2017 , 16 ( 4 ): 375 - 381 .
KATSUYAMA Y . Mining novel biosynthetic machineries of secondary metabolites from actinobacteria [J]. Biosci Biotechnol Biochem , 2019 , 83 ( 9 ): 1606 - 1615 .
YU W , ZHANG J , CHEN Z , et al . Inhibitory effect of a microecological preparation on azoxymethane/dextran sodium sulfate-induced inflammatory colorectal cancer in mice [J]. Front Oncol , 2020 , doi: 10.3389/fonc.2020.562189 http://dx.doi.org/10.3389/fonc.2020.562189 .
WANG L , ZHU Q , LU A , et al . Sodium butyrate suppresses angiotensin Ⅱ-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin-angiotensin system [J]. J Hypertens , 2017 , 35 ( 9 ): 1899 - 1908 .
GONZALEZ-GONZALEZ C , GIBSON T , JAUREGI P . Novel probiotic-fermented milk with angiotensin I-converting enzyme inhibitory peptides produced by bifidobacterium bifidum MF20/5 [J]. Int J Food Microbiol , 2013 , 167 ( 2 ): 131 - 137 .
0
Views
82
下载量
4
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621